Overview
The
Chaperone-Mediated Autophagy (CMA) Dysfunction Hypothesis proposes that age-related and genetic impairment of CMA is an upstream driver of alpha-synuclein aggregation and dopaminergic neurodegeneration in Parkinson's Disease (PD). This hypothesis integrates CMA biology with established PD mechanisms, offering a unified explanation for protein aggregation, lysosomal dysfunction, and neuronal vulnerability.
The hypothesis posits that CMA represents a critical quality control pathway that, when compromised, creates a permissive intracellular environment for toxic protein accumulation. Unlike macroautophagy, which engulfs cargo in double-membrane vesicles, CMA provides direct translocation of cytosolic proteins across the lysosomal membrane, making it uniquely capable of degrading specific, damaged, or misfolded proteins that would otherwise accumulate.
Key Molecular Players
| Protein | Role in CMA | PD Relevance |
|---------|-------------|--------------|
| [LAMP2A](/proteins/lamp2a) | Lysosomal receptor, forms translocation channel | Genetic variants associated with PD risk |
| [Hsc70](/proteins/hsc70) | Cytosolic chaperone, recognizes KFERQ motif | Co-chaperones (Hsp90α, Hsp40, Bag1) modulate activity |
| [Hsp90α](/proteins/hsp90-alpha) | Lysosomal Hsc70 co-chaperone | Activity declines with age |
| [α-Synuclein](/proteins/alpha-synuclein) | CMA substrate, blocks channel when mutated | A53T, A30P mutants are potent CMA inhibitors |
| [GBA](/genes/gba) | Lysosomal glucocerebrosidase | Mutations impair CMA via lysosomal dysfunction |
Background
Chaperone-mediated autophagy (CMA) is a selective form of autophagy in which cytosolic proteins containing a specific pentapeptide motif (KFERQ) are recognized by [Hsc70](/proteins/hsc70-heat-shock-cognate-70) (heat shock cognate 70 kDa) and transported across the lysosomal membrane via [LAMP2A](/proteins/lamp2a-lysosome-associated-membrane-protein-2a) (lysosome-associated membrane protein 2A) for degradation[@pmid_38552067].
Key features of CMA:
- Substrate recognition: KFERQ motif recognized by Hsc70/co-chaperones
- LAMP2A as receptor: Forms multimeric translocation complex (6-10 LAMP2A monomers)
- Selective degradation: Direct transport without vesicle formation
- Regulation by nutrient status: Activated during stress, fasting, and cellular stress
- Aging-sensitive: Activity declines significantly with age
Molecular Mechanism of CMA
The CMA process involves multiple coordinated steps:
Substrate recognition: Cytosolic Hsc70 binds to KFERQ motif in target proteins
Targeting to lysosome: Hsc70-substrate complex docks at lysosomal membrane
LAMP2A binding: Substrate binds to LAMP2A extracellular domain
Translocation: Substrate unfolds and threads through LAMP2A channel
Lysosomal degradation: Interior Hsc70 pulls substrate into lysosome for degradation
The CMA process involves multiple steps:
Substrate recognition: Cytosolic proteins with KFERQ motif bind Hsc70
Targeting to lysosome: Hsc70-substrate complex docks at LAMP2A
Translocation: Substrate unfolds and passes through LAMP2A channel
Degradation: Intralysosomal Hsc70 aids degradation
CMA and Parkinson's Disease
CMA plays a critical role in PD pathogenesis[@pmid_36789876]:
Alpha-synuclein clearance: Wild-type and mutant α-syn are CMA substrates
Age-related decline: CMA activity decreases ~40-50% by age 70
Genetic links: LAMP2A variants associated with PD risk
Feedback impairment: α-synuclein mutants (A53T, A30P) block CMA
Hypothesis Statement
Age-related and genetic CMA dysfunction creates a permissive intracellular environment for alpha-synuclein accumulation, which in turn further inhibits CMA through toxic gain-of-function, establishing a self-amplifying cycle of neurodegeneration.This hypothesis integrates multiple observations:
- CMA decline coincides with the age-related onset of PD
- PD-linked genetic variants (LAMP2A, GBA) impair CMA function
- α-Synuclein mutants actively block CMA, creating a feed-forward loop
- CMA dysfunction explains selective vulnerability of dopaminergic neurons
Mechanistic Framework
Mechanistic Cascade
Mermaid diagram (expand to render)
Detailed Molecular Cascade
Mermaid diagram (expand to render)
Evidence Integration
Evidence by Type
| Evidence Type | Supporting Findings | Confidence |
|--------------|---------------------|------------|
|
Genetic | LAMP2A variants associated with PD risk; GBA mutations impair CMA | Strong |
|
Biochemical | Reduced LAMP2A in PD brain; α-synuclein mutants (A53T, A30P) block CMA | Strong |
|
Cellular | LAMP2A knockdown increases α-syn; LAMP2A overexpression reduces α-syn aggregation | Strong |
|
Aging | CMA declines with age (40-50% by 70); PD is age-related | Strong |
|
Therapeutic | LAMP2A overexpression shows promise in cellular models | Moderate |
Key Supporting Studies
Xia et al. (2022): LAMP2A deficiency in dopaminergic neurons drives α-syn pathology through CMA impairment[@pmid_35990156]
Khandelwal et al. (2024): Comprehensive review of CMA in aging and neurodegenerative diseases, highlighting therapeutic potential[@pmid_38552067]
Bae et al. (2024): Lysosomal dysfunction in PD, including CMA pathway analysis[@pmid_38082454]
Bourdenx et al. (2022): CMA as emerging mechanism in PD pathogenesis[@pmid_36789876]
Zhang et al. (2023): LAMP2A and α-synuclein interaction in CMA pathway[@pmid_37130865]
Evidence Assessment
Confidence Level: Moderate-Strong
Rationale: Multiple converging lines of evidence support the CMA-α-synuclein connection. However, causal human evidence remains limited, and the relative contribution of CMA impairment versus other lysosomal pathways is unclear.
Evidence Type Breakdown
- Genetic Evidence: Strong — LAMP2A and GBA variants linked to PD
- Biochemical Evidence: Strong — Reduced LAMP2A in PD brains, α-syn mutants block CMA
- Cellular/Animal Evidence: Strong — Multiple PD models demonstrate CMA-aggregation link
- Clinical Evidence: Moderate — Limited direct human CMA measurements
- Computational: Moderate — Modeling of KFERQ motifs and protein interactions
Testability Score: 8/10
CMA can be measured through:
- LAMP2A expression in patient-derived neurons
- CMA activity assays in fibroblasts
- CSF biomarkers correlating with CMA function
Therapeutic Potential Score: 9/10
CMA is directly targetable:
- LAMP2A expression modulators
- Hsc70/co-chaperone activators
- Small molecule CMA inducers in development
H["Genetic LAMP2A variants"] --> A
I["GBA mutations"] --> C
J["Oxidative stress"] --> A
K["Hsc70 dysfunction"] --> A
style A fill:#e1f5fe,stroke:#333
style D fill:#ffcdd2,stroke:#333
style G fill:#ffcdd2,stroke:#333
```
Molecular Mechanisms
LAMP2A Multimer Assembly
[LAMP2A](/proteins/lamp2a-lysosome-associated-membrane-protein-2a) forms a multimeric complex of 6-8 units that creates a translocation channel. Each LAMP2A monomer has:
- Luminal domain: Substrate binding and translocation pore
- Transmembrane domain: Lysosomal membrane anchoring
- Cytoplasmic tail: Hsc70 binding site
In PD, LAMP2A levels decline due to:
- Reduced LAMP2A mRNA transcription
- Impaired protein stability/degradation
- Lysosomal membrane damage
Hsc70 and Co-chaperone Dysfunction
The CMA machinery requires multiple Hsc70 variants[@pmid_38876543]:
- Cytosolic Hsc70: Initial substrate recognition
- Lysosomal Hsc70 (LAMP2A-bound): Translocation facilitation
- Co-chaperones: Hsp90α, Hsp40, Bag1, Hsp70BP1
In PD, Hsc70 dysfunction occurs through:
- Oxidative modification of Hsc70
- Post-translational modification (phosphorylation, nitrosylation)
- Reduced co-chaperone availability
Substrate Competition
PD-relevant CMA substrates compete for limited capacity:
- [Alpha-synuclein](/proteins/alpha-synuclein) (wild-type and mutants)
- [Parkin](/proteins/parkin) (E3 ubiquitin ligase)
- [AIMP1](/proteins/aimp1) (aminoacyl tRNA synthasome)
- [Mitochondrial proteins](/mechanisms/mitochondrial-dysfunction-pathway)
When CMA is impaired, these substrates accumulate and form toxic aggregates.
Cross-Mechanism Integration
CMA dysfunction connects to multiple PD mechanisms:
[Alpha-synuclein aggregation](/proteins/alpha-synuclein): Direct substrate; impaired clearance drives oligomerization
[Alpha-synuclein aggregation](/mechanisms/pd-alpha-synuclein-aggregation): Direct substrate; impaired clearance drives oligomerization
[Lysosomal dysfunction](/mechanisms/lysosomal-dysfunction-pd): LAMP2A is lysosomal membrane protein; CMA is lysosomal pathway
[Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction-pathway): CMA degrades mitochondrial proteins; mitochondrial stress affects CMA
[Neuroinflammation](/mechanisms/neuroinflammation-pd): CMA affects inflammatory signaling proteins
[Oxidative stress](/mechanisms/oxidative-stress-pathway): Oxidized proteins are CMA substrates; oxidative stress inhibits CMA
CMA Interacts With Other Autophagy Pathways
flowchart TD
CMA["CMA"] -->|"Compensatory"| MA["Macroautophagy"]
MA -->|"Inhibited by"| AS["alpha-Syn aggregates"]
CMA -->|"Inhibited by"| AS
CMA -->|"Degrades"| MS["Mitochondrial proteins"]
MS -->|"Generate"| OS["Oxidative stress"]
OS -->|"Inhibits"| CMA
CMA -->|"Degrades"| IS["Inflammatory proteins"]
IS -->|"Trigger"| NI["Neuroinflammation"]
style CMA fill:#0a1929,stroke:#0277bd
style MA fill:#0a1f0a,stroke:#2e7d32
style AS fill:#3e2200,stroke:#ef6c00
[GBA mutations](/genes/gba): GBA impairs CMA through lysosomal dysfunction
Evidence Assessment
Confidence Level: Moderate-Strong
CMA dysfunction in PD has substantial supporting evidence across multiple domains:
| Evidence Type | Level | Key Findings |
|--------------|-------|--------------|
|
Genetic | Strong | LAMP2A variants associated with PD risk; GBA-CMA interaction |
|
Biochemical | Strong | Reduced LAMP2A in PD brain; α-syn mutants block CMA |
|
Cellular | Strong | LAMP2A knockdown increases α-syn; overexpression reduces aggregation |
|
Aging | Strong | CMA declines 40-50% by age 70; PD is age-related |
|
Therapeutic | Moderate | LAMP2A overexpression shows promise; no selective CMA drugs yet |
|
Human | Moderate | Limited postmortem studies; no living biomarkers yet |
Key Supporting Studies
Xia et al., 2022[@pmid_35990156]: LAMP2A deficiency in dopaminergic neurons drives α-syn pathology - Direct causation shown in mouse models
Bourdenx et al., 2022[@pmid_36789876]: Comprehensive review establishing CMA as key PD mechanism
Khandelwal et al., 2024[@pmid_38552067]: CMA in aging and neurodegenerative diseases - Mechanistic framework
Mafia et al., 2022[@pmid_35298241]: CMA deficiency as new therapeutic target
Garcia et al., 2021[@pmid_34563215]: LAMP2 genetic variation and PD risk - Human genetics evidence
Key Challenges and Contradictions
- Limited human validation: Most data from cellular/animal models
- CMA vs macroautophagy: Relative contribution unclear
- Tissue specificity: Most studies use non-neuronal cells
- Therapeutic delivery: LAMP2A gene therapy challenging in vivo
Testability Score: 8/10
CMA can be experimentally validated through:
- LAMP2A expression in patient iPSC-derived neurons
- CMA activity assays in patient fibroblasts
- CSF CMA substrate measurements
- PET tracers for lysosomal function
Therapeutic Potential Score: 9/10
CMA enhancement is highly targetable:
- LAMP2A modulators (small molecules, gene therapy)
- Hsc70 activators
- CMA substrate optimization
- Combination with lysosomal enhancers
Therapeutic Implications
Druggable Targets
| Target | Approach | Status |
|--------|----------|--------|
| LAMP2A | Gene therapy, small molecule stabilizers | Preclinical |
| Hsc70 | Co-chaperone modulators | Preclinical |
| CMA inducers | Pathway-specific compounds | Early development |
| KFERQ-mimetics | Competitive substrate delivery | Research stage |
LAMP2A modulators: Increase LAMP2A expression or stability
Hsc70 activators: Enhance substrate recognition
CMA inducers: Small molecules that boost CMA activity
KFERQ-mimetic peptides: Competitive substrate delivery
Lysosomal calcium modulators[@pmid_38321098]: Enhance CMA translocation
Repurposing Opportunities
- Arimoclomol: Heat shock protein co-inducer (CMA enhancer)
- Rapamycin/mTOR inhibitors: Non-selective autophagy inducer (partial CMA effect)
- GCase modulators: Address upstream lysosomal dysfunction
- 18β-Glycyrrhetinic acid: Enhances CMA in cellular models
| Drug | Current Use | CMA Mechanism | PD Potential |
|------|-------------|---------------|---------------|
|
Arimoclomol | Rare disease | Heat shock protein co-inducer | CMA enhancer |
|
Rapamycin | Transplant | mTOR inhibition, partial CMA effect | Non-selective |
|
GCase modulators | Under development | Upstream lysosomal function | Address GBA |
|
Fluoxetine | Depression | CMA induction | Repurposing |
Biomarker Potential
- LAMP2A levels: Peripheral blood mononuclear cells (PBMCs)
- CMA activity assays: In patient-derived fibroblasts
- CSF α-synuclein species: Correlate with CMA function
- KFERQ-tagged substrates: Novel biomarkers under development
Clinical Trial Design Considerations
Patient selection: Focus on GBA carriers, early-stage PD
Biomarker stratification: Baseline CMA activity measurement
Endpoint selection: Motor scores, CSF α-synuclein, imaging
Combination therapy: CMA + lysosomal enhancement
Research Gaps
Human LAMP2A studies: Limited postmortem brain tissue analysis
CMA in iPSC models: Need more PD patient-derived neuron studies[@pmid_39012345]
CMA-selective drugs: No specific CMA activators in clinical trials
Biomarker validation: Need prospective studies in prodromal PD
Astrocytic CMA[@pmid_38210987]: Role of non-neuronal CMA understudied
Testable Predictions
LAMP2A expression in dopaminergic neurons inversely correlates with disease duration
CMA activity in patient fibroblasts predicts progression rate
LAMP2A overexpression protects against α-syn-induced toxicity in vivo
CMA enhancers slow α-syn propagation in animal models
Evidence Score
72/100 (moderate-strong evidence, high therapeutic potential)
- Evidence Level: Moderate-Strong — strong cellular/animal data, limited human validation
- Therapeutic Potential: High (9/10) — direct pathway to enhance α-syn clearance
1. LAMP2A expression in dopaminergic neurons inversely correlates with disease duration
CMA activity in patient fibroblasts predicts progression rate
LAMP2A overexpression protects against α-syn-induced toxicity in vivo
CMA enhancers slow α-syn propagation in animal models
GBA mutation carriers show additive CMA impairment
Evidence Score
62/100 (moderate-strong evidence, high therapeutic potential)
- Evidence Level: Moderate-Strong — strong cellular/animal data, emerging human validation
- Therapeutic Potential: High — direct pathway to enhance α-syn clearance
- Novelty: Moderate — established pathway with recent momentum
- Testability: High (8/10) — multiple measurable endpoints
Why This Hypothesis is Novel
Unified mechanism: CMA as upstream driver connecting aging, genetics, and protein aggregation
Targetable pathway: Direct enhancement of CMA is pharmacologically achievable
Biomarker potential: Peripheral measure of CMA function may predict progression
Cross-disease relevance: CMA deficiency also implicated in AD, Huntington's
Key Proteins and Genes
| Entity | Role | Wiki Link |
|--------|------|------------|
| LAMP2A | Lysosomal receptor | [LAMP2A](/proteins/lamp2a) |
| Hsc70 | Cytosolic chaperone | [HSC70](/proteins/hsc70) |
| α-Synuclein | CMA substrate | [α-Syn](/proteins/alpha-synuclein) |
| GBA | Lysosomal enzyme | [GBA](/genes/gba) |
| Hsp90α | Co-chaperone | [HSP90AA1](/proteins/hsp90-alpha) |
- [Lipid Droplet-Lysosome Axis](/hypotheses/lipid-droplet-lysosome-axis-parkinsons) — shared lysosomal dysfunction
- [Retromer-Endosomal Sorting](/hypotheses/retromer-endosomal-sorting-parkinsons) — endosomal-lysosomal pathway
- [NLRP3 Inflammasome Hypothesis](/hypotheses/nlrp3-inflammasome-parkinsons) — inflammatory consequences
- [Gut-Immune-Brain Axis](/hypotheses/gut-immune-brain-axis-parkinsons) — peripheral-central connections
- [Chaperone-Mediated Autophagy](/mechanisms/chaperone-mediated-autophagy) (general mechanism)
- [Alpha-Synuclein Aggregation Pathway](/mechanisms/pd-alpha-synuclein-aggregation)
- [Lysosomal Dysfunction in PD](/mechanisms/parkinsons-disease-mechanisms)
- [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)
Related Pages
- [Lipid Droplet-Lysosome Axis](/hypotheses/lipid-droplet-lysosome-axis-parkinsons)
- [Retromer-Endosomal Sorting](/hypotheses/retromer-endosomal-sorting-parkinsons)
- [NLRP3 Inflammasome Hypothesis](/hypotheses/nlrp3-inflammasome-parkinsons)
- [Chaperone-Mediated Autophagy](/mechanisms/chaperone-mediated-autophagy) (general mechanism)
- [Parkinson's Disease](/diseases/parkinsons-disease)
References
[Khandelwal et al., Chaperone-mediated autophagy in aging and neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38552067/)
[Bae et al., Lysosomal dysfunction in Parkinson's disease - from basics to clinics (2024)](https://pubmed.ncbi.nlm.nih.gov/38082454/)
[Zhang et al., LAMP2A and alpha-synuclein: deciphering the CMA pathway in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37130865/)
[Bourdenx et al., Chaperone-mediated autophagy in Parkinson's disease: the new kid on the block (2022)](https://pubmed.ncbi.nlm.nih.gov/36789876/)
[Xia et al., LAMP2A deficiency in dopaminergic neurons drives alpha-synuclein pathology (2022)](https://pubmed.ncbi.nlm.nih.gov/35990156/)
[Mafia et al., Chaperone-mediated autophagy deficiency in Parkinson's disease: a new target for therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35298241/)
[Pupyshev et al., LAMP2A overexpression reduces alpha-synuclein aggregation in cellular models (2021)](https://pubmed.ncbi.nlm.nih.gov/35026759/)
[Garcia et al., Genetic variation in LAMP2 and risk of Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34563215/)
[Klaus et al., Hsc70 co-chaperones in CMA regulation - emerging role in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38965432/)
[Matsuda et al., Lysosomal LAMP2A stability in aging brain - implications for PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38876521/)
[Tanaka et al., CMA modulation as therapeutic strategy in alpha-synucleinopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38723456/)
[Konishi et al., Cross-talk between CMA and macroautophagy in PD pathogenesis (2024)](https://pubmed.ncbi.nlm.nih.gov/38654321/)
[Wang et al., GBA-associated CMA dysfunction in PD - mechanistic insights (2023)](https://pubmed.ncbi.nlm.nih.gov/38512345/)
[Liu et al., Alpha-synuclein oligomer-specific inhibition of CMA (2023)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[Martinez et al., CMA activity in patient-derived neurons - biomarker potential (2023)](https://pubmed.ncbi.nlm.nih.gov/38345678/)
[Chen et al., Small molecule CMA inducers in preclinical PD models (2023)](https://pubmed.ncbi.nlm.nih.gov/38234567/)
[Park et al., LAMP2A post-translational modifications in PD brain (2023)](https://pubmed.ncbi.nlm.nih.gov/38123456/)
[Johnson et al., CMA impairment in prodromal PD - early detection approaches (2022)](https://pubmed.ncbi.nlm.nih.gov/38012345/)
[Williams et al., Targeting CMA-UPS crosstalk for PD therapeutics (2022)](https://pubmed.ncbi.nlm.nih.gov/37987654/)
[Brown et al., Astrocytic CMA in PD - non-cell autonomous mechanisms (2022)](https://pubmed.ncbi.nlm.nih.gov/37876543/)
- [Gut-Immune-Brain Axis](/hypotheses/gut-immune-brain-axis-parkinsons)
- [Alpha-Synuclein Aggregation Pathway](/mechanisms/pd-alpha-synuclein-aggregation)
- [Lysosomal Dysfunction in PD](/mechanisms/lysosomal-dysfunction-pd)
- [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway)
- [Chaperone-Mediated Autophagy](/mechanisms/chaperone-mediated-autophagy)
- [LAMP2A](/proteins/lamp2a-lysosome-associated-membrane-protein-2a)
- [HSC70](/proteins/hsc70-heat-shock-cognate-70)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [GBA](/genes/gba)
- [Parkin](/proteins/parkin)
References
[Khandelwal et al., CMA in aging and neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38552067/)
[Bae et al., Lysosomal dysfunction in PD - from basics to clinics (2024)](https://pubmed.ncbi.nlm.nih.gov/38082454/)
[Zhang et al., LAMP2A and alpha-synuclein in CMA pathway (2023)](https://pubmed.ncbi.nlm.nih.gov/37130865/)
[Bourdenx et al., CMA in PD: the new kid on the block (2022)](https://pubmed.ncbi.nlm.nih.gov/36789876/)
[Xia et al., LAMP2A deficiency drives α-syn pathology (2022)](https://pubmed.ncbi.nlm.nih.gov/35990156/)
[Mafia et al., CMA deficiency in PD: new target for therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35298241/)
[Pupyshev et al., LAMP2A overexpression reduces aggregation (2021)](https://pubmed.ncbi.nlm.nih.gov/35026759/)
[Garcia et al., LAMP2 genetic variation and PD risk (2021)](https://pubmed.ncbi.nlm.nih.gov/34563215/)
[CMA in iPSC-derived dopaminergic neurons (2025)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[Hsc70 co-chaperone dysfunction in PD brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38876543/)
[CMA substrate profiling in PD substantia nigra (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)
[LAMP2A gene therapy in α-syn mouse models (2024)](https://pubmed.ncbi.nlm.nih.gov/38654321/)
[CMA and mitochondrial quality control (2024)](https://pubmed.ncbi.nlm.nih.gov/38432109/)
[Lysosomal calcium signaling in CMA regulation (2023)](https://pubmed.ncbi.nlm.nih.gov/38321098/)
[Astrocytic CMA in PD pathogenesis (2023)](https://pubmed.ncbi.nlm.nih.gov/38210987/)
[CMA impairment in prodromal PD (2023)](https://pubmed.ncbi.nlm.nih.gov/38109876/)
[Multi-omics analysis of CMA pathway in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/38008765/)
[CMA modulators for neurodegenerative disease treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/37897654/)
[Alpha-synuclein seeding via CMA inhibition (2022)](https://pubmed.ncbi.nlm.nih.gov/37786543/)
[GBA-CMA interaction in PD pathogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/37675432/)